Quantitative assays for anti-aquaporin-4 antibody with subclass analysis in neuromyelitis optica

Noriko Isobe, Tomomi Yonekawa, Takuya Matsushita, Yuji Kawano, Katsuhisa Masaki, Satoshi Yoshimura, Jakub Fichna, Shu Chen, Jadwiga Furmaniak, Bernard Rees Smith, Jun-Ichi Kira

研究成果: ジャーナルへの寄稿記事

29 引用 (Scopus)

抄録

Background: To clarify the clinical relevance of anti-aquaporin-4 (anti-AQP4) antibody titers and immunoglobulin (IgG) subclass. Methods: Using a bridging enzyme-linked immunosorbent assay (ELISA), a flow cytometric assay (FCMA) and an immunofluorescence assay (IFA) for anti-AQP4 antibodies, sera from 142 patients with multiple sclerosis (MS) as defined by the McDonald criteria (2005), 29 with neuromyelitis optica (NMO) who fulfilled the 1999 criteria, 19 with recurrent and/or longitudinally extensive myelitis (RM/LM), 86 with other non-inflammatory neurological diseases (OND) and 28 healthy controls (HC) were studied. Results: Anti-AQP4 antibody positivity rates by IFA, FCMA, and ELISA were 41.4%, 51.7% and 48.3%, respectively, in NMO (1999) patients, and 0% in the OND and HC groups. Twenty-six MS patients (18.3%) were positive for the antibody; 17 met the 2006 NMO criteria, including positivity for anti-AQP4 antibody, and five had longitudinally extensive myelitis (LM). Among the cases with anti-AQP4 antibody detected by FCMA, IgG1, 2, 3, and 4 anti-AQP4 antibodies were found in 97.8%, 37.0%, 6.5% and 6.5% respectively. There was no association of either antibody positivity or level of anti-AQP4 antibody IgG subclasses with clinical parameters after adjustment of p values for multiple comparisons. Conclusions: FCMA and bridging ELISA are useful for detecting and quantifying anti-AQP4 antibodies.

元の言語英語
ページ(範囲)1541-1551
ページ数11
ジャーナルMultiple Sclerosis Journal
18
発行部数11
DOI
出版物ステータス出版済み - 1 1 2012

Fingerprint

Aquaporin 4
Neuromyelitis Optica
Antibodies
Myelitis
Immunoglobulin G
Enzyme-Linked Immunosorbent Assay
Multiple Sclerosis
Fluorescent Antibody Technique
Immunoglobulins
Anti-Idiotypic Antibodies

All Science Journal Classification (ASJC) codes

  • Neurology
  • Clinical Neurology

これを引用

Quantitative assays for anti-aquaporin-4 antibody with subclass analysis in neuromyelitis optica. / Isobe, Noriko; Yonekawa, Tomomi; Matsushita, Takuya; Kawano, Yuji; Masaki, Katsuhisa; Yoshimura, Satoshi; Fichna, Jakub; Chen, Shu; Furmaniak, Jadwiga; Smith, Bernard Rees; Kira, Jun-Ichi.

:: Multiple Sclerosis Journal, 巻 18, 番号 11, 01.01.2012, p. 1541-1551.

研究成果: ジャーナルへの寄稿記事

Isobe, Noriko ; Yonekawa, Tomomi ; Matsushita, Takuya ; Kawano, Yuji ; Masaki, Katsuhisa ; Yoshimura, Satoshi ; Fichna, Jakub ; Chen, Shu ; Furmaniak, Jadwiga ; Smith, Bernard Rees ; Kira, Jun-Ichi. / Quantitative assays for anti-aquaporin-4 antibody with subclass analysis in neuromyelitis optica. :: Multiple Sclerosis Journal. 2012 ; 巻 18, 番号 11. pp. 1541-1551.
@article{5fe6e261216b4ee589ced0663ebae10f,
title = "Quantitative assays for anti-aquaporin-4 antibody with subclass analysis in neuromyelitis optica",
abstract = "Background: To clarify the clinical relevance of anti-aquaporin-4 (anti-AQP4) antibody titers and immunoglobulin (IgG) subclass. Methods: Using a bridging enzyme-linked immunosorbent assay (ELISA), a flow cytometric assay (FCMA) and an immunofluorescence assay (IFA) for anti-AQP4 antibodies, sera from 142 patients with multiple sclerosis (MS) as defined by the McDonald criteria (2005), 29 with neuromyelitis optica (NMO) who fulfilled the 1999 criteria, 19 with recurrent and/or longitudinally extensive myelitis (RM/LM), 86 with other non-inflammatory neurological diseases (OND) and 28 healthy controls (HC) were studied. Results: Anti-AQP4 antibody positivity rates by IFA, FCMA, and ELISA were 41.4{\%}, 51.7{\%} and 48.3{\%}, respectively, in NMO (1999) patients, and 0{\%} in the OND and HC groups. Twenty-six MS patients (18.3{\%}) were positive for the antibody; 17 met the 2006 NMO criteria, including positivity for anti-AQP4 antibody, and five had longitudinally extensive myelitis (LM). Among the cases with anti-AQP4 antibody detected by FCMA, IgG1, 2, 3, and 4 anti-AQP4 antibodies were found in 97.8{\%}, 37.0{\%}, 6.5{\%} and 6.5{\%} respectively. There was no association of either antibody positivity or level of anti-AQP4 antibody IgG subclasses with clinical parameters after adjustment of p values for multiple comparisons. Conclusions: FCMA and bridging ELISA are useful for detecting and quantifying anti-AQP4 antibodies.",
author = "Noriko Isobe and Tomomi Yonekawa and Takuya Matsushita and Yuji Kawano and Katsuhisa Masaki and Satoshi Yoshimura and Jakub Fichna and Shu Chen and Jadwiga Furmaniak and Smith, {Bernard Rees} and Jun-Ichi Kira",
year = "2012",
month = "1",
day = "1",
doi = "10.1177/1352458512443917",
language = "English",
volume = "18",
pages = "1541--1551",
journal = "Multiple Sclerosis",
issn = "1352-4585",
publisher = "SAGE Publications Ltd",
number = "11",

}

TY - JOUR

T1 - Quantitative assays for anti-aquaporin-4 antibody with subclass analysis in neuromyelitis optica

AU - Isobe, Noriko

AU - Yonekawa, Tomomi

AU - Matsushita, Takuya

AU - Kawano, Yuji

AU - Masaki, Katsuhisa

AU - Yoshimura, Satoshi

AU - Fichna, Jakub

AU - Chen, Shu

AU - Furmaniak, Jadwiga

AU - Smith, Bernard Rees

AU - Kira, Jun-Ichi

PY - 2012/1/1

Y1 - 2012/1/1

N2 - Background: To clarify the clinical relevance of anti-aquaporin-4 (anti-AQP4) antibody titers and immunoglobulin (IgG) subclass. Methods: Using a bridging enzyme-linked immunosorbent assay (ELISA), a flow cytometric assay (FCMA) and an immunofluorescence assay (IFA) for anti-AQP4 antibodies, sera from 142 patients with multiple sclerosis (MS) as defined by the McDonald criteria (2005), 29 with neuromyelitis optica (NMO) who fulfilled the 1999 criteria, 19 with recurrent and/or longitudinally extensive myelitis (RM/LM), 86 with other non-inflammatory neurological diseases (OND) and 28 healthy controls (HC) were studied. Results: Anti-AQP4 antibody positivity rates by IFA, FCMA, and ELISA were 41.4%, 51.7% and 48.3%, respectively, in NMO (1999) patients, and 0% in the OND and HC groups. Twenty-six MS patients (18.3%) were positive for the antibody; 17 met the 2006 NMO criteria, including positivity for anti-AQP4 antibody, and five had longitudinally extensive myelitis (LM). Among the cases with anti-AQP4 antibody detected by FCMA, IgG1, 2, 3, and 4 anti-AQP4 antibodies were found in 97.8%, 37.0%, 6.5% and 6.5% respectively. There was no association of either antibody positivity or level of anti-AQP4 antibody IgG subclasses with clinical parameters after adjustment of p values for multiple comparisons. Conclusions: FCMA and bridging ELISA are useful for detecting and quantifying anti-AQP4 antibodies.

AB - Background: To clarify the clinical relevance of anti-aquaporin-4 (anti-AQP4) antibody titers and immunoglobulin (IgG) subclass. Methods: Using a bridging enzyme-linked immunosorbent assay (ELISA), a flow cytometric assay (FCMA) and an immunofluorescence assay (IFA) for anti-AQP4 antibodies, sera from 142 patients with multiple sclerosis (MS) as defined by the McDonald criteria (2005), 29 with neuromyelitis optica (NMO) who fulfilled the 1999 criteria, 19 with recurrent and/or longitudinally extensive myelitis (RM/LM), 86 with other non-inflammatory neurological diseases (OND) and 28 healthy controls (HC) were studied. Results: Anti-AQP4 antibody positivity rates by IFA, FCMA, and ELISA were 41.4%, 51.7% and 48.3%, respectively, in NMO (1999) patients, and 0% in the OND and HC groups. Twenty-six MS patients (18.3%) were positive for the antibody; 17 met the 2006 NMO criteria, including positivity for anti-AQP4 antibody, and five had longitudinally extensive myelitis (LM). Among the cases with anti-AQP4 antibody detected by FCMA, IgG1, 2, 3, and 4 anti-AQP4 antibodies were found in 97.8%, 37.0%, 6.5% and 6.5% respectively. There was no association of either antibody positivity or level of anti-AQP4 antibody IgG subclasses with clinical parameters after adjustment of p values for multiple comparisons. Conclusions: FCMA and bridging ELISA are useful for detecting and quantifying anti-AQP4 antibodies.

UR - http://www.scopus.com/inward/record.url?scp=84863988174&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84863988174&partnerID=8YFLogxK

U2 - 10.1177/1352458512443917

DO - 10.1177/1352458512443917

M3 - Article

C2 - 22526930

AN - SCOPUS:84863988174

VL - 18

SP - 1541

EP - 1551

JO - Multiple Sclerosis

JF - Multiple Sclerosis

SN - 1352-4585

IS - 11

ER -